Study of Anlotinib in Patients With Primary Malignant Bone Tumors

NCT03527888 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasm of Bone

Interventions

DRUG: Anlotinib

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.